(Aurora, Ontario) – Helix BioPharma Corp. (“Helix”) (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has established a Polish subsidiary (“Helix Polska”). Helix Polska was established to facilitate and support ongoing clinical oncology research at leading research institutions in Poland.
- 0 Comments
- FY2014